文献速递关节外科

合成大麻素屈大麻酚不能减少全膝关节置换术后阿片类药物用量:一项前瞻性随机三盲安慰剂对照研究

A Synthetic Form of Cannabinoid Does Not Decrease Opioid Use After Total Knee Arthroplasty: A Prospective, Randomized, Triple-Blind, Placebo-Controlled Study.
PubMed 文献 · J Arthroplasty · 2026-03-31

研究纳入163例初次单侧全膝关节置换术患者,随机分为屈大麻酚组(2.5 mg每日两次,n=81)与安慰剂组(n=82),患者、提供者、统计师及研究团队均设盲。主要结局为术后两周阿片类药物吗啡毫克当量(MME),结果显示两组在住院期间MME(40.1±74.8 vs 38.8±76.4,P=0.901)及两周总MME(383.6±309.8 vs 367.6±246.3,P=0.717)均无差异。结论认为该合成delta-9-四氢大麻酚(sTHC)不能限制初次全膝关节置换术后的阿片类药物摄入。

要点

  • 屈大麻酚组与安慰剂组在住院期间和术后两周阿片类药物用量均无显著差异。
  • 两组在疼痛、睡眠、恶心呕吐及患者报告结局方面亦无差异。
  • 基于此数据,THC可能对全膝关节置换术后患者无获益。

核心结论

  • 合成delta-9-四氢大麻酚(sTHC)屈大麻酚不能减少初次全膝关节置换术后的阿片类药物摄入。
  • 基于这些数据,THC可能对全膝关节置换术后患者无获益。

研究设计与样本

  • 前瞻性、随机、三盲、安慰剂对照研究,纳入163例接受初次单侧全膝关节置换术的患者。
  • 患者随机接受屈大麻酚2.5 mg每日两次(n=81)或安慰剂片2.5 mg每日两次(n=82),作为疼痛管理的辅助。
  • 患者、提供者、统计师和研究团队均设盲;患者为大麻初治者,术前进行药物筛查;无论分组均接受标准围手术期多模式疼痛方案(包括阿片类药物)。

主要发现

  • 住院期间阿片类药物MME消耗:sTHC组40.1±74.8 vs 安慰剂组38.8±76.4,P=0.901。
  • 术后两周总MME:sTHC组383.6±309.8 vs 安慰剂组367.6±246.3,P=0.717。
  • 术后两周和四周自报疼痛(P=0.581;0.710)、每晚睡眠小时数(P=0.103;0.140)及恶心呕吐(P=0.689;0.158)两组无差异。
  • 术后六周患者报告结局指标两组无差异,两组均未观察到药物或安慰剂相关并发症。

临床怎么用

  • 对于接受初次全膝关节置换术且为大麻初治的患者,不应期望使用屈大麻酚来减少术后阿片类药物用量。
  • 临床决策应基于标准围手术期多模式疼痛方案,而非添加sTHC作为辅助以限制阿片类药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Self-reported cannabis use in patients undergoing total knee arthroplasty (TKA) has increased since its legalization. Despite endorsement, its efficacy has never been studied in a prospective randomized study in orthopaedic surgery. The purpose of this study was to determine whether a synthetic delta-9-tetrahydrocannabinol (sTHC), dronabinol, decreases opioid use after TKA. METHODS: There were 163 patients who underwent primary unilateral TKA who were prospectively randomized into receiving dronabinol (2.5 mg twice a day, n = 81) versus a placebo pill (2.5 mg twice a day, n = 82) as an adjunct to pain management. Patients, providers, our statistician, and the research team were blinded to the groups. Patients were cannabis naïve and had drug screening prior to surgery. Patients received our standard perioperative multimodal pain regimen (including opioids) regardless of randomization. The primary outcome was opioid morphine milligram equivalents (MME) at two weeks. Secondary outcomes included self-reported pain, sleep scores, nausea/vomiting, knee range of motion, and patient-reported outcomes. Patients were followed for six weeks after TKA. Statistical significance was accepted at P ≤ 0.05. RESULTS: There were no differences for in-hospital MME consumed (sTHC 40.1 ± 74.8 versus placebo 38.8 ± 76.4, P = 0.901), or in total MME noted at two weeks (sTHC 383.6 ± 309.8 versus placebo 367.6 ± 246.3, P = 0.717). Self-reported pain (P = 0.581; 0.710), hours of sleep per night (P = 0.103; 0.140), and nausea/vomiting (P = 0.689; 0.158) showed no differences between the groups at two and four weeks. No differences in patient-reported outcome measures at six weeks were noted between groups. There were no drug- or placebo-related complications were noted in either group. CONCLUSIONS: Despite enthusiasm for cannabis after orthopaedic surgical procedures, this sTHC does not appear to limit opioid intake after primary TKA. Based on these data, THC may offer no benefit for patients after TKA.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Jennings JM, Dennis DA, Miner TM, et al. A Synthetic Form of Cannabinoid Does Not Decrease Opioid Use After Total Knee Arthroplasty: A Prospective, Randomized, Triple-Blind, Placebo-Controlled Study. J Arthroplasty. 2026. PMID: 41967982. doi:10.1016/j.arth.2026.02.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。